Satellos Bioscience Inc · TSX:MSCL

Satellos Bioscience — Investor Presentation (February 2026)

21 slides from Satellos Bioscience's investor presentation, February 2026

1. Slide 1: Regenerating Muscle From Within

   © 2026 Satellos Bioscience R E G E N E R AT I N G M U S C L E F R O M W I T H I N T M

2. Slide 2: Legal Disclaimers

   © 2026 Satellos Bioscience Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any The information contained herein is subject to change without statements that express or involve discussions with respect to predictions, expect

3. Slide 3: Grounded in science. Inspired by need.

   © 2026 Satellos Bioscience Grounded in science. Inspired by need. Our mission is to improve the treatment of Duchenne muscular dystrophy (DMD) and other devastating muscle diseases by restoring the body’s natural ability to regenerate muscle. CHARLIE, age 8, living with Duchenne 3

4. Slide 4: SAT-3247: Making Regeneration Happen

   © 2026 Satellos Bioscience SAT-3247: Making Regeneration Happen Why SAT-3247 Clear Clinical Path Demonstrated is different for SAT-3247 Strength Gains  Oral, disease modifying therapy  Regulatory clearances and initiation  Progressive strength gains in DMD designed for safety & tolerability of BA

5. Slide 5: Muscle Regeneration Fails in DMD

   © 2026 Satellos Bioscience Muscle Regeneration Fails in DMD Infants 2 to 4 years 5 to 9 years 10 to 12 years 13 to 19 years 20 years + Muscle growth exceeds loss. Tipping Point Regeneration Fails Muscle loss Functional capacity is preserved > gains Progressive and continuous muscle loss Satellos dis

6. Slide 6: Why Regeneration Fails in DMD

   © 2026 Satellos Bioscience Why Regeneration Fails in DMD DMD Patients Lack Sufficient Muscle Progenitor Cells Needed to Make New Muscle Clinical Confirmation DMD Patients Have an Excess of Muscle Stem vs. Progenitor Cells +ve nuclei / muscle cell Muscle stem cells Muscle progenitor cells DMD patient

7. Slide 7: Satellos Discovery: Why There is a Shortage of Muscle Progenitor Cells

   © 2026 Satellos Bioscience Satellos Discovery: Why There is a Shortage of Muscle Progenitor Cells Loss of dystrophin disrupts production of progenitors Repair & Regeneration Repair & Regeneration Healthy Muscle DMD Muscle One One Failed Production of Two Muscle Progenitor Cell Muscle Stem Cell Muscl

8. Slide 8: Satellos Discovery: Progenitor Formation & Regeneration Can Be Restored

   © 2026 Satellos Bioscience Satellos Discovery: Progenitor Formation & Regeneration Can Be Restored Inhibition of AAK1 with SAT-3247 Replaces Missing Dystrophin Signal Repair & Regeneration Repair & Regeneration DMD Muscle Restored in DMD Failed Production of Two One One Muscle Progenitor Cells Muscl

9. Slide 9: Preclinical POC and Ph 1 Clinical Data

   © 2026 Satellos Bioscience Preclinical POC and Ph 1 Clinical Data

10. Slide 10: SAT-3247 Treatment Shows Promising Effects in Canine Model

    © 2026 Satellos Bioscience SAT-3247 Treatment Shows Promising Effects in Canine Model Muscle Strength Increased in Canine Model Muscle Regeneration Enhanced in Canine Model 2x and 4x @ 2 and 4 months @ 4 months Flexion Tetanic Torque N/kg 100um Before After Healthy Treatment Treatment Animal Months

11. Slide 11: SAT-3247 Phase 1 First-in-Human Clinical Trial

    © 2026 Satellos Bioscience SAT-3247 Phase 1 First-in-Human Clinical Trial Ph 1a: Healthy Volunteers (n=72) Ph 1b: DMD Adults SAD* Study MAD* Study 28-day, Open-Label Study  10 - 400 mg  60 - 240 mg  60 mg daily dose, weekdays only for 4 weeks  5 cohorts of 8  4 cohorts of 8  5 patients enrolle

12. Slide 12: SAT-3247: Safe and Well-Tolerated in Phase 1 with Desired PK Profile

    © 2026 Satellos Bioscience SAT-3247: Safe and Well-Tolerated in Phase 1 with Desired PK Profile Key Demographics Pharmacokinetic Profiling SAD/FE (n=40) MAD (n=32) Ph 1b (n=5) Safety Summary SAD (n=40) MAD (n=32) FE (n=8) Ph 1b (n=5) Phase 1 Takeaway SAT-3247 demonstrated a favorable safety profile

13. Slide 13: SAT-3247: Promising Indications of Functional Effect in Days

    © 2026 Satellos Bioscience SAT-3247: Promising Indications of Functional Effect in 28 Days 5.8% Increase in 118.6% and 97.9% Increases in Predicted Forced Vital Capacity (FVC) Grip Strength in Dominant and Non-Dominant hands Mean change Individual Dominant Hand Non-Dominant Hand +5.8% Patients n=4 n

14. Slide 14: Increased Grip Strength with SAT-3247 Exceeds Natural History

    © 2026 Satellos Bioscience Increased Grip Strength with SAT-3247 Treatment Exceeds Results Seen in Natural History Duchenne natural history a SAT-3247 overlay with natural history IMPROVEMENT  Improvement with SAT-3247 beyond what is reported for natural history  Consistently below 10 kg after age

15. Slide 15: Grip Strength Improvements Correlate with Cmax and Creatinine Levels

    © 2026 Satellos Bioscience Grip Strength Improvements Correlate with Cmax and Creatinine Levels Supports rationale that results seen are drug related Maximum Grip Strength vs Cmax Maximum Grip Strength vs Baseline Creatinine Spearmen correlations: Spearmen correlations: Dominant hand – 0.9 Dominant

16. Slide 16: Inside Satellos

    © 2026 Satellos Bioscience Inside Satellos Future plans and the team executing them

17. Slide 17: Current Clinical Trials to Evaluate SAT-3247 in People with DMD

    © 2026 Satellos Bioscience Current Clinical Trials to Evaluate SAT-3247 in People with DMD LT-001 BASECAMP (CL-201) 51 ambulatory DMD participants aged ≥ 7 and < 10 Participants 10 adults with DMD >=18 years years of age Will assess the long-term safety, Will study 60 and 120 mg of SAT-3247 in a tol

18. Slide 18: 2026 Clinical Trial Catalysts: Quarterly Momentum

    © 2026 Satellos Bioscience 2026 Clinical Trial Catalysts: Quarterly Momentum Q1 Q2 Q3 Q4  LT-001: Grip & FVC,  LT-001: Grip & FVC,  LT-001: Grip & FVC,  LT-001: Grip & FVC, Biomarkers Biomarkers, MRI Biomarkers Biomarkers, MRI  BASECAMP: Site initiation &  BASECAMP: Interim data  BASECAMP: In

19. Slide 19: Financial Summary

    © 2026 Satellos Bioscience Financial Summary Balance sheet supports activities to execute on upcoming milestones TSX MSCL Research Analyst Coverage Q3 2025 cash balance Canaccord Tania Armstrong-Whitworth US$34.6M Oppenheimer Kostas Biliouris Common shares outstanding 223,424,093* H.C. Wainwright Ar

20. Slide 20: Management Team

    © 2026 Satellos Bioscience Management Team Biotech CPA with 20 years Neuromuscular Neuroscientist with entrepreneur with of biotech finance disease expert with 25+ years of drug 20+ company experience. 10+ years in clinical discovery launches, $500M+ Former CFO of development. experience. in financi

21. Slide 21: Reimagine, Regenerate, Realize

    Reiniagine how muscle degeneration is treated. Regenerate with small molecule medicines. Realize the next horizon to improve lives. satellos REGENERATING MUSCLE FROM WITHIN™

Satellos Bioscience — Investor Presentation (February 2026) on 6ix